ES2729568T3 - Composición farmacéutica para el tratamiento de infecciones por VIH - Google Patents
Composición farmacéutica para el tratamiento de infecciones por VIH Download PDFInfo
- Publication number
- ES2729568T3 ES2729568T3 ES13867546T ES13867546T ES2729568T3 ES 2729568 T3 ES2729568 T3 ES 2729568T3 ES 13867546 T ES13867546 T ES 13867546T ES 13867546 T ES13867546 T ES 13867546T ES 2729568 T3 ES2729568 T3 ES 2729568T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- use according
- composition comprises
- cellulose
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012158141/15A RU2505286C1 (ru) | 2012-12-29 | 2012-12-29 | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
PCT/RU2013/000817 WO2014104929A1 (ru) | 2012-12-29 | 2013-09-19 | Фармацевтическая композиция для лечения вич-инфекции |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2729568T3 true ES2729568T3 (es) | 2019-11-04 |
Family
ID=49957619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13867546T Active ES2729568T3 (es) | 2012-12-29 | 2013-09-19 | Composición farmacéutica para el tratamiento de infecciones por VIH |
Country Status (18)
Country | Link |
---|---|
US (1) | US10493034B2 (da) |
EP (1) | EP2939665B1 (da) |
CN (1) | CN104884050A (da) |
CA (1) | CA2896710C (da) |
CY (1) | CY1121660T1 (da) |
DK (1) | DK2939665T3 (da) |
EA (1) | EA029586B1 (da) |
ES (1) | ES2729568T3 (da) |
HR (1) | HRP20190882T1 (da) |
HU (1) | HUE043694T2 (da) |
LT (1) | LT2939665T (da) |
PL (1) | PL2939665T3 (da) |
PT (1) | PT2939665T (da) |
RS (1) | RS58837B1 (da) |
RU (1) | RU2505286C1 (da) |
SI (1) | SI2939665T1 (da) |
TR (1) | TR201908007T4 (da) |
WO (1) | WO2014104929A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194687A (zh) * | 2015-10-22 | 2015-12-30 | 浙江医药高等专科学校 | 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法 |
WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
RU2616267C1 (ru) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения |
EP4320233A1 (en) | 2021-04-07 | 2024-02-14 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
WO2024085784A1 (ru) * | 2022-10-19 | 2024-04-25 | Общество С Ограниченной Ответственностью "Промомед Рус" | Фармацевтическая композиция и лекарственное средство для лечения коронавирусной инфекции |
WO2024091148A2 (ru) * | 2022-10-26 | 2024-05-02 | Общество С Ограниченной Ответственностью "Абицея Медикал Технолоджис" | Жидкий бальнеологический концентрат и ампула с мерной шкалой и устройством для удобного дозирования бальнеологического концентрата |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
WO2008017867A2 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition with at least one water insoluble polymer |
GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
KR20100134557A (ko) * | 2008-01-11 | 2010-12-23 | 씨아이피엘에이 엘티디. | 고체 약제학적 투여 제형 |
EP2304043A4 (en) * | 2008-07-09 | 2012-05-30 | Purdue Research Foundation | HIV PROTEASE INHIBITORS AND METHOD FOR THEIR USE |
EP2279728A1 (en) * | 2009-07-31 | 2011-02-02 | Ranbaxy Laboratories Limited | Solid dosage forms of HIV protease inhibitors |
CA2837266A1 (en) * | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
US20150004237A1 (en) * | 2012-01-09 | 2015-01-01 | Virginia Tech Intellectual Properties, Inc. | Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs |
US20150045400A1 (en) * | 2012-03-01 | 2015-02-12 | Bandi Parthasaradhi Reddy | Ritonavir compositions |
WO2014184553A1 (en) * | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
-
2012
- 2012-12-29 RU RU2012158141/15A patent/RU2505286C1/ru active
-
2013
- 2013-09-19 DK DK13867546.7T patent/DK2939665T3/da active
- 2013-09-19 TR TR2019/08007T patent/TR201908007T4/tr unknown
- 2013-09-19 CA CA2896710A patent/CA2896710C/en not_active Expired - Fee Related
- 2013-09-19 EA EA201500710A patent/EA029586B1/ru unknown
- 2013-09-19 RS RS20190656A patent/RS58837B1/sr unknown
- 2013-09-19 HU HUE13867546A patent/HUE043694T2/hu unknown
- 2013-09-19 PT PT13867546T patent/PT2939665T/pt unknown
- 2013-09-19 CN CN201380068729.6A patent/CN104884050A/zh active Pending
- 2013-09-19 PL PL13867546T patent/PL2939665T3/pl unknown
- 2013-09-19 SI SI201331474T patent/SI2939665T1/sl unknown
- 2013-09-19 WO PCT/RU2013/000817 patent/WO2014104929A1/ru active Application Filing
- 2013-09-19 LT LTEP13867546.7T patent/LT2939665T/lt unknown
- 2013-09-19 EP EP13867546.7A patent/EP2939665B1/en active Active
- 2013-09-19 ES ES13867546T patent/ES2729568T3/es active Active
-
2015
- 2015-06-29 US US14/753,395 patent/US10493034B2/en not_active Expired - Fee Related
-
2019
- 2019-05-14 HR HRP20190882TT patent/HRP20190882T1/hr unknown
- 2019-05-29 CY CY20191100564T patent/CY1121660T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2939665B1 (en) | 2019-03-20 |
HRP20190882T1 (hr) | 2019-09-20 |
EP2939665A1 (en) | 2015-11-04 |
SI2939665T1 (sl) | 2019-08-30 |
LT2939665T (lt) | 2019-07-25 |
RS58837B1 (sr) | 2019-07-31 |
US10493034B2 (en) | 2019-12-03 |
PT2939665T (pt) | 2019-06-14 |
CA2896710A1 (en) | 2014-07-03 |
EA029586B1 (ru) | 2018-04-30 |
CA2896710C (en) | 2019-03-26 |
EA201500710A1 (ru) | 2015-10-30 |
CN104884050A (zh) | 2015-09-02 |
RU2505286C1 (ru) | 2014-01-27 |
CY1121660T1 (el) | 2020-07-31 |
PL2939665T3 (pl) | 2020-01-31 |
US20150297526A1 (en) | 2015-10-22 |
HUE043694T2 (hu) | 2019-09-30 |
DK2939665T3 (da) | 2019-06-11 |
TR201908007T4 (tr) | 2019-06-21 |
EP2939665A4 (en) | 2016-06-01 |
WO2014104929A1 (ru) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2729568T3 (es) | Composición farmacéutica para el tratamiento de infecciones por VIH | |
ES2430849T3 (es) | Formas de dosificación sólidas biodisponibles de metaxalona | |
ES2950995T3 (es) | Un comprimido que comprende un derivado de metoxiurea y partículas de manitol | |
Singh et al. | Fast disintegrating combination tablets of omeprazole and domperidone | |
CN101784263B (zh) | 奈韦拉平的延长释放制剂 | |
Jeevanandham et al. | Formulation and evaluation of naproxen sodium orodispersible tablets –A sublimation technique | |
Furtado et al. | Development and characterization of orodispersible tablets of famotidine containing a subliming agent | |
KR102286386B1 (ko) | 아타자나비르 및 코비시스타트의 hiv 치료 제제 | |
Senthilnathan et al. | Formulation development and evaluation of venlafaxine hydrochloride orodispersible tablets | |
ES2483154T3 (es) | Formulaciones farmacéuticas sólidas de ramipril y besilato de amlodipino y su preparación | |
Karen et al. | Development of oral strip for loratadine and in vitro evaluation | |
ES2901598T3 (es) | Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo | |
Kumar et al. | Development and characterization of melt-in-mouth tablets of haloperidol by sublimation technique | |
Tabbakhian et al. | Formulation and evaluation of orally disintegrating tablet of Rizatriptan using natural superdisintegrant | |
Kumar et al. | Formulation and evaluation of piroxicam fast dissolving tablets using direct compression and sublimation method | |
Murugesan et al. | Formulation and Evaluation of Ranolazine Fast Dissolving Tablets Using Various Superdisintegrants | |
Mishra et al. | Formulation and evaluation of mouth dissolving tablets of carvedilol | |
Rahim et al. | Disintegrants combination: development and optimization of a cefadroxil fast disintegrating tablet. | |
Abdel Halim | Formulation of new sildenafil citrate-caffeine orally disintegrating tablets: in vitro and in vivo evaluation | |
Ranch Ketan et al. | Formulation, design and optimization of orodispersible tablets of atenolol | |
RU2659693C1 (ru) | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции | |
RU2760129C1 (ru) | Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства | |
Tekade et al. | Orodispersible tablets of lansoprazole: Formulation, characterization and in vitro evaluation | |
RU2543322C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения | |
Nasser et al. | Preparation and Evaluation of Oral Disintegrating Tablets of Ketoprofen by Dirct Compression |